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Abstract
Clinical researchers in acute emergency settings are commonly faced with the difficulty of satisfying the
conventional ethical requirement of obtaining informed consent, whilst ensuring a representative group
of patients is recruited into studies. We discuss our own experience in addressing institutional ethical
requirements to obtain informed consent in a multi-centre trial, recruiting highly agitated patients in the
emergency setting in Melbourne, Australia. We suggest that, through the application of existing ethical
and legal frameworks and pre-emptive communication with the key stakeholders in ethics committees,
hospital insurers and legal representatives, a balance can be struck between ethical and legal require-
ments on the one hand, and the integrity of the research question, on the other.
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‘A 33-year-old male, of average build, is
brought into the Emergency Department (ED)
by police. He is severely agitated, aggressive, is
threatening staff and kicking doors. An internal
hospital alert is called and security staff are
mobilised. De-escalation measures have failed
and you see an urgent need for chemical
restraint (drug sedation) to reduce the risk of
harm to the patient or others. The need for
sedation deems the patient eligible for inclusion
into a clinical trial which compares several drug
alternatives in this setting. Before proceeding
with immediate study drug administration,
what are the issues relating to informed con-
sent? The patient is clearly incompetent to con-
sent and no next of kin or legal representative is
available. How can consent be obtained in these
circumstances?’
This vignette outlines a typical scenario we
have been faced with in the conduct of a study
currently underway in three EDs across
Melbourne, Australia. The study aims to assess
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the efficacy of sedating agent regimens, with the
primary outcome being the time taken to
achieve adequate sedation. Simply excluding
all such patients would severely compromise
our study both in terms of the number of
patients recruited and the generalisability of
the sample. It would become biased towards
those less severely ill. In anticipation of such
scenarios, we engaged in pre-emptive discus-
sions with local institutional research ethics
committees and legal representatives regarding
how to work within their frameworks to
deliver the imperatives of this study. This paper
describes that process and outlines some clinical
scenarios we have faced in the conduct of the
study thus far. However, first, we expand on
the context in which the study is being
conducted.
ACUTELY AGITATED PATIENTS
IN THE ED SETTING
Highly agitated patients are unable to make
informed decisions regarding treatment options
or informed consent for participation in clinical
research. Accordingly, the value of consent
obtained from such patients is questionable.
Furthermore, consent obtained under such con-
ditions may be similar to involuntary submission
(Lewin et al. 2006). Other investigators evaluat-
ing treatments for acute agitation have also
acknowledged the difficulty in obtaining mean-
ingful and truly informed consent prior to
enrolment into the study (Damsa et al. 2008;
Nobay et al. 2004; Martel et al. 2005; Knott
et al. 2006; TREC Collaborative Group, 2003).
One approach to dealing with this has been
to take consent from the patient after the inter-
vention has been instituted. This provides
patients with an opportunity to withdraw (as is
their right), data are then destroyed and the
patient is excluded from analyses. However, dif-
ficulties arise with obtaining patient consent
post enrolment in studies such as ours, as a con-
siderable proportion of patients with underlying
mental illness may need to be sedated for
extended periods after their ED visit. They
may be transferred to an acute psychiatric unit
or another institution prior to recovery from
sedation or behavioural disturbance. The logis-
tical difficulties in tracing these patients and
approaching them at an appropriate time would
be considerable or not possible. Patients who
are sedated due to the effects of recreational
drugs or alcohol are commonly belligerent and
uncooperative even upon discharge. It is not
uncommon that they leave against medical
advice or abscond.
Furthermore, selection bias may still be intro-
duced by failing to obtain consent from patients
who, when incapacitated, were randomised and
administered the study drugs. Those patients
able to provide informed consent are likely less
agitated than those unable to provide consent.
Secondly, inability to consent and use data
already collected on some patients (due to
ongoing mental illness, refusal, loss to follow
up) would result in additional patients being
randomised and administered the study drugs.
Consequently, the number of patients rando-
mised may be well in excess of the required
sample size. This outcome would be undesir-
able from the patient perspective and would
add cost, logistical difficulties and delays to the
study. Indeed, these factors present ethical issues
in their own right. Finally, all patients rando-
mised should be included in the analysis under
the ‘intention to treat’ principle. If consent can-
not be obtained subsequently, this principle is
technically breached and additional selection
bias may be introduced.
An alternative to ‘post hoc’ consent is to
approach a family member to act as a surrogate
for decision making. This approach has been
sanctioned and has a place in certain research
scenarios (American Medical Association, unpub.
report, 2004: http://www.ama-assn.org/ama/
pub/physician-resources/medical-ethics/code-
medical-ethics/opinion8081.shtml). However,
again, there are logistical difficulties in obtaining
informed consent from family members or other
‘responsible persons’ prior to sedation, in a study
such as ours. The greatest barrier is their lack of
availability at the time an emergency interven-
tion (i.e. rapid sedation) is required. Also, there
is the possibility that the patient may blame the
family member for having ‘given’ consent to
such an intervention, on their behalf.
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RESOLVING THE
REQUIREMENTS FOR INFORMED
CONSENT
There is no single strategy for managing the
process of obtaining emergency consent, due
to variability in hospital and institutional ethics
committees’ policies, and local legislation. The
issues surrounding informed consent are com-
plex and specific. Fortunately, there is provision
for waiver of consent in such circumstances.
However, this process can be protracted, and
requires consultation amongst all key stake-
holders including the study principal investig-
ator, study site investigators, hospital staff
members involved in the study, institutional
ethics committees, hospital insurers and legal
representatives. There is potential for patient
and public involvement in the design of such
clinical studies to help investigators improve
the study methodology and protocol develop-
ment. Such studies may be better accepted by
participants regardless of their capacity to pro-
vide informed consent at the time of entry
into the trial. This might serve to minimise
the potential for bias, secondary to the sub-
sequent withdrawal of patient consent.
In terms of our study, we decided proactively
to engage the aforementioned stakeholders from
all the participating sites, early in the study
design and ethical application process. After
the initial institutional ethics application, a
meeting was convened with the chair of the
institutional ethics committee, a representative
of the hospital, a lawyer representing the hos-
pital insurers and the study investigators. At
this meeting, the inherent difficulties of obtain-
ing informed consent from this particular
patient group, the medical condition and study
design were discussed with respect to the feasib-
ility of obtaining informed consent pre- or post-
sedation, either from the patient themselves or a
legal representative. At the conclusion of the
meeting, all parties were satisfied that the local
legislation (The Victorian Guardianship and
Administration Act 1986) satisfactorily covered
the absence of patient consent for the purpose
of this study. This decision was accepted by
the institutional ethics committees of all parti-
cipating institutions, and ethical approval was
granted. Specifically, the Human Research Eth-
ics Committee (HREC) consulted section 4.4.6
of the National Statement on Ethical Conduct
in Human Research (National Health and
Medical Research Council et al. 2007) in their
deliberations and was satisfied that the condi-
tions for waiver of consent were met. The
National Statement (2007) acknowledges that
‘in emergency care research, recruitment into
a research project often has to be achieved
rapidly. . .’ and states that ‘. . .consent for the
research may be waived provided the condi-
tions of paragraph 2.3.6 (page 24) are satisfied.’
A set of nine conditions are outlined under
paragraph 2.3.6, one of which is that HREC
must be satisfied that ‘it is impracticable to
obtain consent (for example, due
to. . .accessibility. . .)’ (National Health and
Medical Research Council et al. 2007).
While specific legislation or national state-
ments on human research will differ depending
on the location of practice and research, the pro-
cess of prompt identification of the key stake-
holders in resolving consent issues and the
arrangement of meetings can be generally
applied in different practice settings. Through
prompt proactive engagement of stakeholders,
much time was saved in extensive electronic
communication, delays in waiting for replies
and responding to requests for clarifications. In
our experience, this was critical in achieving an
efficient outcome for all parties. Given the
complexity of this issue, every effort should be
undertaken to convene a meeting with all
stakeholders in attendance. It also provides an
opportunity to discuss and examine existing
acts and regulations, which may be a challenge
to interpret.
EXISTING LEGAL AND ETHICAL
FRAMEWORKS
The enrolment of such patients into clinical
research is governed by medical ethics, state
and federal legislation. The World Medical
Association Declaration of Helsinki (2008),
the European Directive on clinical trials (Euro-
pean Parliament, 2001) and the Nuffield
Council documents on bioethics suggest that
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non-consenting patients are permitted in trials
on two grounds: where no other context exists
in which to answer the question and where all
trial participants get clear therapeutic benefit
from whichever arm they are randomised to
(Huf et al. 2002). The World Medical Associ-
ation Declaration of Helsinki (2008) offers
provisions for studies to proceed even when
informed consent is not provided by the
patient or a legally authorised representative,
given that the reasons for involving subjects
with a condition that renders them unable to
give informed consent is stated in the research
protocol and is approved by the institutional
research ethics committee.
With respect to the management of behavi-
oural disturbance, there are variations in mental
health legislation between the US, UK, Austra-
lia and New Zealand. However, the respect for
individual autonomy and the use of least
restrictive management practices is consistent
amongst all legislation (Phillips et al. 2009).
Such legislation allows provisions for the admis-
sion, assessment and treatment of people unable
to make medical treatment decisions for various
reasons to avoid posing danger to themselves or
others.
EDs provide an easy entry point for people
with mental health problems, including those
temporarily incapacitated due to external factors
including intoxication of drugs and alcohol, and
situational crisis. Generally, under all Australian
and New Zealand mental health acts, doctors
are empowered by legislation to detain a men-
tally ill or incapacitated person who is in need
of assessment and treatment. (Phillips et al.
2009).
In Australia, each state is governed by state
mental health legislation. Specifically, in Vic-
toria, Australia, the legal requirements for the
emergency medical treatment of such patients
is set out in Section 42A of the Guardianship
and Administration Act 1986 (Vic) (GAA),
where ‘a registered practitioner may carry out. . .
treatment on a patient without consent. . .if the
practitioner believes on reasonable grounds
that the treatment is necessary, as a matter of
urgency. . .to save the patient’s life; or to prevent
serious damage to the patient’s health’. The pro-
vision for the recruitment of patients who lack
the capacity to provide informed consent for
the purposes of medical research, are set out in
Section 42E of the GAA. Within the GAA, a
‘medical research procedure’ is defined as ‘a pro-
cedure carried out for the purposes of medical
research, including, as part of a clinical trial,
the administration of medication or the use of
equipment or a device’. Studies that satisfy this
definition may be acceptable in the absence of
informed consent. However, this would depend
on individual and locally specific circumstances.
SUMMARY AND CONCLUSIONS
Medical ethical documents and legislation are in
place to protect individuals and provide guid-
ance to conduct clinical research. Current med-
ical ethical statements provide some provision
for clinical research to proceed without prior
patient consent. However, these should be
interpreted alongside legislation that is relevant
to the study-site(s) and applied to support study
protocols and institutional ethical submissions.
Early facilitation of meetings with key stake-
holders is important to ensure an understanding
of study intentions and to resolve any queries
surrounding informed consent for the specific
patient group under study. This will lead to
more speedy ethical approvals and improve the
efficiency of clinical research in such settings.
There are regulations which permit waiver of
informed consent in specific circumstances in
the United States, Canada and Australia (Largent
et al. 2010). However, researchers should be
aware, that whilst patients may lack the capacity
to provide informed consent to participate in
research, this does not mean that such patients
may be automatically recruited into clinical
studies. Investigators must be familiar with the
legislation that offers provisions to proceed
with their research prior to obtaining patient
consent.
In conclusion, whilst resolving the need for
informed consent in an emergency clinical
research setting can be challenging, satisfactory
resolution that respects ethical and legal consid-
erations is possible.
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